HIT to LEAD to Candidate development of a Transcription Repressor Inhibitory Compound (TRIC), which switches off bacterial resistance to a broad band antibiotic

• Research unit: INNOSUISSE
• Project number: 12667.1;4 PFLS-LS

Short description (German)

HIT to LEAD to Candidate development of a Transcription Repressor Inhibitory Compound (TRIC), which switches off bacterial resistance to a broad band antibiotic

Short description (English)

HIT to LEAD to Candidate development of a Transcription Repressor Inhibitory Compound (TRIC), which switches off bacterial resistance to a broad band antibiotic

Abstract (German)

A new and highly innovative treatment will be realized by a novel and patentable orally available small molecule combinatorial drug candidate for the treatment of antibiotic resistance in multi-resistant, pathogenic bacterial strains. The consortium integrates medicinal chemistry (Dr. Riedl, ZHAW), biological assays and screening (BioVersys AG) with high-end characterization of binding interactions (Prof. Dr. Gygax, FHNW). HIT compounds identified during two SATW projects will be developed into a clinical candidate utilizing all the experiences in the consortium.

Abstract (English)

A new and highly innovative treatment will be realized by a novel and patentable orally available small molecule combinatorial drug candidate for the treatment of antibiotic resistance in multi-resistant, pathogenic bacterial strains. The consortium integrates medicinal chemistry (Dr. Riedl, ZHAW), biological assays and screening (BioVersys AG) with high-end characterization of binding interactions (Prof. Dr. Gygax, FHNW). HIT compounds identified during two SATW projects will be developed into a clinical candidate utilizing all the experiences in the consortium.